Skip to content

Incyte INCY Total costs & expenses

Total costs & expenses at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Gilead Sciences logo
Gilead SciencesGILD
Amgen logo
AmgenAMGN
Biogen logo
BiogenBIIB
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$1.3B+20.9%
Gross profit$1.2B+19.2%
Operating income$301.1M+46.8%
Net income$303.3M+91.7%
EPS (diluted)$1.47+83.8%

Balance sheet

See full
Cash & equivalents$3.5B+78.2%
Total debt$39.4M-8.6%
Total equity$5.6B+53.3%
Total assets$7.3B+27.7%

Cash flow

See full
Operating cash flow$369.4M+38.8%
CapEx$1.6M-43.5%
Free cash flow$367.7M+39.7%

Valuation

See full
Market cap$19.78B+59.9%
Enterprise value$16.35B+55.9%
P/E13.8×-568×
P/S3.7×+0.9×

Profitability

See full
Gross margin92.5%-0.2pp
Operating margin30%+26.1pp
Net margin26.7%+26.2pp

Returns & leverage

See full
Return on equity30.8%+30.4pp
Debt / equity0.0×
Current ratio3.7×+1.6×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The official record: Incyte’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's total costs & expenses?
Incyte (INCY) reported total costs & expenses of $971.56M in Q1 2026.
How has Incyte's total costs & expenses changed year-over-year?
Incyte's total costs & expenses increased by 14.6% year-over-year, from $847.73M to $971.56M.
What is the long-term trend for Incyte's total costs & expenses?
Over 4 years (2021 to 2025), Incyte's total costs & expenses has grown at a 10.9% compound annual growth rate (CAGR), from $2.4B to $3.63B.